Search results for "BEACOPP"

showing 5 items of 5 documents

Osteonecrosis in Hodgkin lymphoma treated by BEACOPP

2018

BEACOPPOncologymedicine.medical_specialtyVincristineCyclophosphamidebusiness.industrymedicine.medical_treatmentProcarbazineBleomycin030218 nuclear medicine & medical imaging03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistryPrednisone030220 oncology & carcinogenesisInternal medicineInternal MedicinemedicineDoxorubicinbusinessEtoposidemedicine.drugInternal Medicine Journal
researchProduct

Osteonecrosis detected by whole body magnetic resonance (WB-MRI) in patients with Hodgkin lymphoma treated by BEACOPP

2016

Purpose: The purpose of our retrospective study was to assess the incidence of osteonecrosis in patients who received different chemotherapies. Methods and Materials: We evaluated the Whole Body Magnetic Resonance (WB-MRI) scans performed on 42 patients with Hodgkin Lymphoma treated by three chemotherapy regimens (6 ABVD, 2 ABVD + 4 BEACOPP, 2 ABVD + 8 BEACOPP), excluding the patients with main risk factors for osteonecrosis. Results: Six out of 7 patients (85.7%) who received 8 BEACOPP and 1 out of 5 patients (20%) treated by 4 BEACOPP presented osteonecrosis, with a statistically significant difference of frequency between the two groups of patients (p<0.05); no injury has been reporte…

LymphomaOsteonecrosisWhole Body ImagingMagnetic ResonanceBEACOPP
researchProduct

Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin Lymphoma treated by BEACOPP

2016

Objectives: The purpose of our retrospective review of prospectively acquired Whole Body Magnetic Resonance (WB-MRI) scans was to assess the incidence of osteonecrosis in patients who received different chemotherapies. Methods: We evaluated the WB-MRI scans performed on 42 patients with Hodgkin Lymphoma treated by three chemotherapy regimens (6ABVD, 2ABVD + 4BEACOPP, 2ABVD + 8BEACOPP), excluding patients with the main risk factors for osteonecrosis. Results: Six out of seven patients (86 %) who received eight BEACOPP and one out of five patients (20 %) treated by four BEACOPP presented osteonecrosis, with a statistically significant difference of frequency between the two groups of patients…

MaleBEACOPPLymphomamedicine.medical_treatmentProcarbazine030218 nuclear medicine & medical imaging0302 clinical medicinePrednisoneAntineoplastic Combined Chemotherapy ProtocolsMedicineWhole Body ImagingEtoposideIncidenceOsteonecrosisGeneral MedicineMiddle AgedHodgkin DiseaseMagnetic Resonance ImagingVincristine030220 oncology & carcinogenesisOsteonecrosiFemaleRadiologymedicine.drugAdultVincristinemedicine.medical_specialtyAdolescentCyclophosphamideDrug Administration ScheduleBleomycinYoung Adult03 medical and health sciencesImage Interpretation Computer-AssistedHumansRadiology Nuclear Medicine and imagingCyclophosphamideGlucocorticoidsNeoplasm StagingRetrospective StudiesDose-Response Relationship Drugbusiness.industrymedicine.diseaseLymphomaABVDDoxorubicinProcarbazinePrednisonebusinessComplicationBEACOPPEuropean Radiology
researchProduct

Osteonecrosi individuate mediante RM whole body in pazienti con Linfoma di Hodgkin trattati mediante BEACOPP.

2016

Scopo: Il trattamento del Linfoma di Hodgkin (LH) ha condotto al raggiungimento di elevati tassi di sopravvivenza [1]. Il protocollo ABVD (Doxorubicina, Bleomicina, Vinblastina e Dacarbazina) è stato considerato per molto tempo il regime chemioterapico standard nei pazienti con LH [2], grazie a una ben documentata efficacia e una scarsa tossicità. Molti studi hanno dimostrato la maggiore efficacia del protocollo BEACOPP (Bleomicina, Etoposide, Doxorubicina, Ciclofosfamide, Vincristina, Procarbazina, Prednisone) rispetto all'ABVD [3], al costo di una maggiore tossicità. L'osteonecrosi [ON] è una possibile complicanza della chemioterapia che può compromettere la qualità di vita del paziente, …

Risonanza Magnetica Whole BodyLinfomaOsteonecrosiBEACOPP
researchProduct

Overall survival impact of BEACOPP versus ABVD in advanced hodgkin lymphoma: a pooled analysis of 4 randomized trials

2016

IF 6.671; International audience

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologySurvival impact[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyABVD[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHodgkin lymphomaBEACOPPChimiothérapie
researchProduct